

GPTHEALTH/CS/SE/2024-25

March 28, 2025

The Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400001 Scrip Code: 544131	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Symbol: GPTHEALTH
ISIN: INE486R01017	

Dear Sir/Madam

Sub: Intimation of receipt of Cautionary Email and Cautionary Letter from NSE and BSE under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to the above cited subject, the Company was in receipt of a Cautionary email dated March 28, 2025 from NSE and a Cautionary Letter from BSE Limited vide Reference No. LIST/COMP/JP/1769/2024-25 dated March 28, 2025 regarding delay in disclosure to Stock Exchanges in respect of the intimation of Schedule of Investors/ Analysts' Meet/ Call held on June 19, 2024 as required under sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.

The information in terms of Regulation 30 of SEBI Listing Regulations, in the prescribed format, is given below:

1	Name of the Authority	NSE and BSE Limited
2	Nature and details of the action(s) taken, initiated or order(s) passed	Cautionary Email and Cautionary Letter
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	March 28, 2025
4	Details of the violation(s)/ contravention(s) committed or alleged to be committed.	Delay in disclosure to Stock Exchanges in respect of the intimation of Schedule of Investors/ Analysts' Meet/ Call held on June 19, 2024 as required under sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.	No Impact

The Company will take necessary action as advised in the aforesaid email and letter.

Kindly take the aforesaid information on record and oblige.

Thanking You,
Yours sincerely,

For GPT Healthcare Limited

Ankur Sharma
Company Secretary and Compliance Officer
M. No A31833

Encl: A/a

Ankur Sharma

From: neaps@nse.co.in
Sent: 28 March 2025 17:31
To: GHIL Cosec
Subject: GPTHEALTH - Cautionary Email

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on June 14, 2024 regarding the intimation of Schedule of Investors/ Analysts Meet/call to be held on June 19, 2024.

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary email on the Stock Exchanges where they are listed.

Additionally, the Company is advised to place before their Board of Directors this Cautionary email and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

This is system generated email, you may reach out to the Announcements Team in case of any assistance at takeover@nse.co.in.

Ankur Sharma

From: Query lodr <query.lodr@bseindia.com>
Sent: 28 March 2025 16:22
To: Ankur Sharma
Subject: Cautionary Letter

LIST/COMP/JP/1769/2024-25

Date: March 28, 2025

To,
Company Secretary /Compliance Officer
GPT Healthcare Ltd (544131)

Sub: Cautionary letter

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on June 14, 2024, regarding the intimation of Schedule of Investors/ Analysts' Meet/ Call to be held on June 19, 2024

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet/call).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary Letter on the Stock Exchanges where they are listed. Additionally, the Company is advised to place before their Board of Directors this Cautionary Letter and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

Yours faithfully,

Listing Compliance Monitoring Team
BSE Limited
P J Towers, Dalal Street,
Mumbai - 400001, India
www.bseindia.com
Tel: 022 2272 8561 / 8475

This mail is classified as 'CONFIDENTIAL' by chetan.ag on March 28, 2025 at 16:21:41.

DISCLAIMER : The contents of this message may be legally privileged and confidential and are for the use of the intended recipient(s) only. It should not be read, copied and used by anyone other than the intended recipient(s). If you have received this message in error, please immediately notify the sender, preserve its confidentiality and delete it. Before opening any attachments please check them for viruses and defects. DISCLAIMER : The contents of this message may be legally privileged and confidential and are for the use of the intended recipient(s) only. It should not be read, copied and used by anyone other than the intended recipient(s). If you have received this message in error, please immediately notify the sender, preserve its confidentiality and delete it. Before opening any attachments please check them for viruses and defects.